Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Amber C. King, PharmD, BCOP, and Jennifer S. Orozco, PharmD
Department of Clinical Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York
Authors’ disclosures of conflicts of interest are found at the end of this article.
Amber C. King, PharmD, BCOP, Memorial Sloan Kettering Cancer Center—Clinical Pharmacy, 1275 York Avenue, New York, New York 10065. E-mail: email@example.com
J Adv Pract Oncol 2019;10(8):878–882 |
© 2019 Harborside™
Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy in relapsed and refractory diffuse large B-cell lymphoma (DLBCL) patients who have had suboptimal responses to conventional therapies. The immune activation that confers the efficacy of axi-cel comes at the price of potentially devastating adverse phenomena: cytokine release syndrome and neurotoxicity. This article serves as an overview of axi-cel, including a review of the available clinical evidence, mechanism of action, and management of some of the unique toxicities of axi-cel.
For access to the full length article, please sign in